Arvinas (ARVN)
(Delayed Data from NSDQ)
$24.82 USD
-0.12 (-0.48%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $24.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 21 - 40 ( 210 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Palbo Combo Shows Impressive Efficacy; Bodes Well for VERITAC-3
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ARVN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Degrader Data Supports Pipeline Reprioritization Concerning ARV-766; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Bevdeg Makes Way for ARV-766; Upgrading to OUTPERFORM
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-471 Palbociclib Combination Might Be Superior To SOC-Our Thoughts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Ph 3 VERITAC-2 and 3 Trials Officially Underway
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-766 Shows Potential Against Multiple AR Mutants, Though Data is Early
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Our Insights on the ARV-471''s Phase 1b/2 Combo Trial Update; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2023 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Roundup For 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D